Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 of oxycellidine combined with ciprofol for movement suppression during painless induced abortion
ChiCTR2500100406Phase 4Recruiting
- Sponsor
- Jiaxing Second Hospital
- Start
- Apr 2025
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ciprofol in abortion, sponsored by Jiaxing Second Hospital. Primary endpoints: Movement response and ED50 of oxycellidine (with ciprofol) for movement suppression. Started Apr 2025; status: recruiting.
02
Drugs
ciprofol
03
Conditions
abortion
Beyond the preview
Go deeper on ChiCTR2500100406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100406.